Suppr超能文献

微小RNA-210作为糖尿病相关内皮功能障碍的治疗靶点

miR-210 as a therapeutic target in diabetes-associated endothelial dysfunction.

作者信息

Collado Aida, Jiao Tong, Kontidou Eftychia, Carvalho Lucas Rannier Ribeiro Antonino, Chernogubova Ekaterina, Yang Jiangning, Zaccagnini Germana, Zhao Allan, Tengbom John, Zheng Xiaowei, Rethi Bence, Alvarsson Michael, Catrina Sergiu-Bogdan, Mahdi Ali, Carlström Mattias, Martelli Fabio, Pernow John, Zhou Zhichao

机构信息

Division of Cardiology, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden.

Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.

出版信息

Br J Pharmacol. 2025 Jan;182(2):417-431. doi: 10.1111/bph.17329. Epub 2024 Oct 14.

Abstract

BACKGROUND AND PURPOSE

MicroRNA (miR)-210 function in endothelial cells and its role in diabetes-associated endothelial dysfunction are not fully understood. We aimed to characterize the miR-210 function in endothelial cells and study its therapeutic potential in diabetes.

EXPERIMENTAL APPROACH

Two different diabetic mouse models (db/db and Western diet-induced), miR-210 knockout and transgenic mice, isolated vessels and human endothelial cells were used.

KEY RESULTS

miR-210 levels were lower in aortas isolated from db/db than in control mice. Endothelium-dependent relaxation (EDR) was impaired in aortas from miR-210 knockout mice, and this was restored by inhibiting miR-210 downstream protein tyrosine phosphatase 1B (PTP1B), mitochondrial glycerol-3-phosphate dehydrogenase 2 (GPD2), and mitochondrial oxidative stress. Inhibition of these pathways also improved EDR in both diabetic mouse models. High glucose reduced miR-210 levels in endothelial cells and impaired EDR in mouse aortas, effects that were reversed by overexpressing miR-210. However, plasma miR-210 levels were not affected in individuals with type 2 diabetes (T2D) following improved glycaemic status. Of note, genetic overexpression using miR-210 transgenic mice and pharmacological overexpression using miR-210 mimic in vivo ameliorated endothelial dysfunction in both diabetic mouse models by decreasing PTP1B, GPD2 and oxidative stress. Genetic overexpression of miR-210 altered the aortic transcriptome, decreasing genes in pathways involved in oxidative stress. miR-210 mimic restored decreased nitric oxide production by high glucose in endothelial cells.

CONCLUSION AND IMPLICATIONS

This study unravels the mechanisms by which down-regulated miR-210 by high glucose induces endothelial dysfunction in T2D and demonstrates that miR-210 serves as a novel therapeutic target.

LINKED ARTICLES

This article is part of a themed issue Non-coding RNA Therapeutics. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v182.2/issuetoc.

摘要

背景与目的

微小RNA(miR)-210在内皮细胞中的功能及其在糖尿病相关内皮功能障碍中的作用尚未完全明确。我们旨在明确miR-210在内皮细胞中的功能,并研究其在糖尿病治疗中的潜力。

实验方法

使用了两种不同的糖尿病小鼠模型(db/db小鼠和西式饮食诱导的小鼠)、miR-210基因敲除小鼠和转基因小鼠、分离的血管以及人内皮细胞。

关键结果

从db/db小鼠分离的主动脉中miR-210水平低于对照小鼠。miR-210基因敲除小鼠主动脉的内皮依赖性舒张(EDR)受损,通过抑制miR-210下游的蛋白酪氨酸磷酸酶1B(PTP1B)、线粒体甘油-3-磷酸脱氢酶2(GPD2)和线粒体氧化应激可使其恢复。抑制这些途径也改善了两种糖尿病小鼠模型的EDR。高糖降低了内皮细胞中miR-210的水平,并损害了小鼠主动脉的EDR,而过表达miR-210可逆转这些作用。然而,2型糖尿病(T2D)患者血糖状况改善后,血浆miR-210水平未受影响。值得注意的是,在两种糖尿病小鼠模型中,使用miR-210转基因小鼠进行基因过表达以及在体内使用miR-210模拟物进行药物过表达,均可通过降低PTP1B、GPD2和氧化应激来改善内皮功能障碍。miR-210的基因过表达改变了主动脉转录组,减少了氧化应激相关途径中的基因。miR-210模拟物可恢复高糖导致的内皮细胞一氧化氮生成减少。

结论与意义

本研究揭示了高糖导致miR-210下调从而诱导T2D内皮功能障碍的机制,并表明miR-210是一个新的治疗靶点。

相关文章

本文是主题为“非编码RNA治疗学”的一部分。若要查看本节中的其他文章,请访问http://onlinelibrary.wiley.com/doi/10.1111/bph.v182.2/issuetoc。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验